BIOA
BioAge Labs, Inc.
NASDAQ · Healthcare · Biotechnology · US
$9.59
+0.95%Aug 13, 2026, 07:34 UTC
Dimensional Fund Advisors LP acquired a new position of 214,546 shares in BioAge Labs, Inc. during the first quarter, valued at approximately $3,746,000, as disclosed in its Form 13F filing.
Source:Aug 6, 2026, 01:36 UTC
BioAge Labs, Inc. reported a second-quarter loss of $0.58 per share, beating the Zacks Consensus Estimate of a loss of $0.65 and improving from a loss of $0.60 per share a year earlier.
Source:Aug 5, 2026, 20:50 UTC
BioAge Labs dosed the first participant in QUELL-CV, a Phase 2 dose-ranging proof-of-concept trial of BGE-102 measuring inflammatory and cardiometabolic biomarkers, with topline data anticipated in the second half of 2026.
Source:Jul 31, 2026, 17:24 UTC
BioAge Labs Inc. stock plunged on Friday after disappointing Phase 3 cardiovascular trial results from Novo Nordisk A/S raised concerns about NLRP3-targeting therapies.
Source: